WO2024012317A1 - 一种用于抵抗衰老的组合物及其用途或方法 - Google Patents

一种用于抵抗衰老的组合物及其用途或方法 Download PDF

Info

Publication number
WO2024012317A1
WO2024012317A1 PCT/CN2023/105802 CN2023105802W WO2024012317A1 WO 2024012317 A1 WO2024012317 A1 WO 2024012317A1 CN 2023105802 W CN2023105802 W CN 2023105802W WO 2024012317 A1 WO2024012317 A1 WO 2024012317A1
Authority
WO
WIPO (PCT)
Prior art keywords
days
composition
fibrosis
therapeutic agent
tissue
Prior art date
Application number
PCT/CN2023/105802
Other languages
English (en)
French (fr)
Inventor
王瑞琦
梁坤
郑子鹏
苗译心
杨婕
Original Assignee
爱医谷(苏州)生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 爱医谷(苏州)生物科技有限公司 filed Critical 爱医谷(苏州)生物科技有限公司
Publication of WO2024012317A1 publication Critical patent/WO2024012317A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to the field of small molecule compounds, and in particular, to a composition for anti-aging and its use.
  • Aging is associated with the progressive degeneration of tissues, which negatively affects the structure and function of vital organs and is one of the most important known risk factors for most chronic diseases. Given that the proportion of the world's population over 60 years old will double in the next 40 years, the increased incidence of age-related chronic diseases will place a huge burden on medical resources. Aging is characterized by the progressive accumulation of damage, leading to loss of physiological integrity, impaired function, and increased vulnerability to death.
  • the purpose of the present invention is to overcome the defects existing in the prior art, that is, all drugs on the market cannot effectively treat or prevent aging. After extensive experiments and repeated explorations, the inventor of the present application discovered a composition for resisting aging.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutic agent X or a pharmaceutically acceptable salt thereof, wherein the therapeutic agent X is selected from the group consisting of compounds of general formula (I) or general formula (II) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is capable of promoting cell or tissue expansion or growth.
  • the pharmaceutical composition is capable of allowing cells or sustained expansion for at least 4 days, 5 days, 6 days, 8 days, 9 days, 10 days, 20 days, 30 days, 40 days, 50 days, 100 days days, 150 days, 200 days, 300 days, 400 days or even more days.
  • the pharmaceutical combinations may be used to prevent or treat cellular or tissue fibrosis.
  • the pharmaceutical combinations may be used with cells or tissues selected from cells or tissues derived from endoderm, ectoderm, mesoderm or germline.
  • the pharmaceutical combination can be used to prevent or treat aging-related diseases or symptoms selected from the group consisting of amyotrophy, cachexia, disuse atrophy, myopathy, alopecia cardiomyopathy, skin wrinkles, baldness, Macular degeneration, hepatic steatosis, steatohepatitis, type 2 diabetes (T2D), chronic obstructive pulmonary disease (COPD), osteoarthritis, osteoporosis, fibrosis, Alzheimer's disease, Parkinson's disease, dementia atherosclerosis sclerosis, cardiovascular disease, arthritis, rheumatoid arthritis, periodontitis, cataracts, osteoporosis, fibrosis, cirrhosis, idiopathic pulmonary fibrosis, cardiac fibrosis fibrosis, uterine fibrosis, scars, arthrofibrosis, chronic kidney disease, Crohn's disease, keloids, myelofibrosis, retroperitoneal fibrosis, scler
  • the pharmaceutical combination is administered to an individual or subject over the age of 40.
  • the present invention provides a composition comprising a therapeutic agent X or a pharmaceutically acceptable salt thereof, wherein the therapeutic agent X is selected from the group consisting of compounds of general formula (I) or general formula (II) or Its pharmaceutically acceptable salt.
  • the composition is capable of promoting cell or tissue expansion or growth.
  • the composition is capable of allowing cells or sustained expansion for at least 4 days, 5 days, 6 days, 8 days, 9 days, 10 days, 20 days, 30 days, 40 days, 50 days, 100 days , 150 days, 200 days, 300 days, 400 days or even more days.
  • the combination can be used to prevent or treat cellular or tissue fibrosis.
  • the combinations may be used with cells or tissues selected from cells or tissues derived from endoderm, ectoderm, mesoderm or germline.
  • the composition can be used to increase physical endurance.
  • compositions can be used to relieve fatigue. In some embodiments, the compositions can be used to relieve exercise fatigue.
  • compositions may be used for nutritional supplementation.
  • compositions may be used to improve appearance (eg, but not limited to, bodybuilding, wrinkle removal, hair growth, hair volume increase, hair loss prevention).
  • the compositions may be added to nutraceuticals, dietary supplements, sports drinks, or nutritional formulations.
  • the composition may be added to a health product, dietary supplement, sports drink, or nutritional formulation, wherein in the health product, dietary supplement, sports drink, or nutritional formulation, the composition
  • the proportion of ingredients does not exceed 99.9%, 99.5%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 97% , 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70 %, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, 49%, 48%, 47%, 46%, 45%,
  • the composition can be added to a protein source or food.
  • the composition may be added to a protein source or food, wherein the proportion of ingredients of the composition in the protein source or food is no more than 70%, 69%, 68%, 67 %, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%, 37%, 36%, 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25% ,24%,23%,22%,21%,20%,19%,18%,17%,16%,15%14%,13%,12%,11%,10%,9%,8% , 7%, 6%, 5%, 4%, 3%, 2%
  • the composition may be added to cosmetics, nutraceuticals or cosmeceuticals.
  • the composition can be added to cosmetics, health cosmetics or cosmeceuticals, wherein the proportion of ingredients of the composition in the cosmetics, health cosmetics or cosmeceuticals is no more than 99% , 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 97%, 86%, 85%, 84%, 83%, 82 %, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, 49% ,48%,47%,46%,45%,44%,43%,42%,41%,
  • Figure 1 shows the use of varying concentrations of sodium plus salt of Therapeutic Agent Treatment of senescent human skeletal muscle (Hskm) cells.
  • the sodium salt addition of 100-200 ⁇ M therapeutic agent X (general formula I) can significantly promote the proliferation of skeletal muscle cells.
  • Cholate in the figure refers to the sodium salt of therapeutic agent X (formula I).
  • Figure 2 shows the proliferation rate of senescent skeletal muscle cells (relative to 0 multiple changes in days).
  • the sodium salt addition of 100-200 ⁇ M therapeutic agent X (general formula I) can significantly increase the proliferation rate of skeletal muscle cells.
  • Cholate in the figure refers to the sodium salt of therapeutic agent X (formula I).
  • Figure 3 shows the proliferation rate of senescent skeletal muscle cells (relative to 0 multiple changes in days).
  • the sodium salt addition of 100-200 ⁇ M therapeutic agent X (general formula I) can significantly increase the proliferation rate of skeletal muscle cells.
  • Cholate in the figure refers to the sodium salt of therapeutic agent X (formula I).
  • Figure 4 shows the myogenic gene expression status of skeletal muscle cells after treatment with different concentrations of therapeutic agent X (general formula II) for 4 days. Twist2 and Myh3 in the picture are both myogenic genes, and GAPDH is a housekeeping gene used to benchmark and quantify the expression of myogenic genes. Myh3 levels indicate that 100 ⁇ M Therapeutic Agent X (Formula II) reduces terminal differentiation of skeletal muscle cells. 1mM is too high and promotes terminal differentiation.
  • Figure 5 shows the treatment of skeletal muscle cells with different concentrations of Therapeutic Agent X (Formula II) compared to the dimethyl sulfoxide vehicle control group (control group). 100 ⁇ M Therapeutic Agent X (Formula II) significantly increased skeletal muscle cell proliferation.
  • Figure 6 shows the proliferation rate of skeletal muscle cells after treatment with different concentrations of therapeutic agent X (general formula II) for 4 days compared with the dimethyl sulfoxide vehicle control group (con). 100 ⁇ M Therapeutic Agent X (Formula II) significantly increased skeletal muscle cell proliferation.
  • Anti-aging pharmaceutical composition and use (or method) thereof are provided.
  • the present invention provides a pharmaceutical composition for anti-aging, which includes therapeutic agent X or a pharmaceutically acceptable salt thereof.
  • compositions and/or dosage forms means, within the scope of reasonable medical judgment, suitable for use in contact with human and animal tissue without undue toxicity, irritation, allergic reactions or other problems or complications, and with reasonable benefit /risk ratio commensurate with those compounds, materials, compositions and/or dosage forms.
  • Therapeutic Agent X may form stable pharmaceutically acceptable acid or base salts, and in such cases it may be appropriate to administer the compound as a salt.
  • therapeutic agent X may be present in the pharmaceutical composition in a therapeutically effective amount.
  • therapeutically effective amount refers to an amount of a compound or composition sufficient to significantly and positively alter the symptom and/or condition to be treated (eg, to provide a positive clinical response).
  • the effective amount of the active ingredient used in the pharmaceutical composition will vary depending on the specific condition being treated, the severity of the condition, the duration of treatment, the nature of concurrent therapy, the specific active ingredient employed, and the specific pharmaceutically acceptable excipient utilized. vary with similar factors within the agent, as well as the attending physician's knowledge and expertise.
  • treatment refers to a method used to obtain beneficial or desired clinical results.
  • treating means inhibiting, preventing or arresting the development or progression of a pathology (disease, disorder or condition) and/or causing the alleviation, remission or regression of the pathology.
  • pathology disease, disorder or condition
  • alleviation, remission or regression of the pathology Those skilled in the art will appreciate that various methods and assays can be used to assess the development of pathology, and similarly, various methods and assays can be used to assess the alleviation, remission, or regression of pathology.
  • prevention means preventing the occurrence of a disease, disorder or condition in a subject who may be at risk for the disease but has not yet been diagnosed with the disease. Prevention (and the dose for effective prevention) can be demonstrated in population studies. For example, an effective amount to prevent a given disease or medical condition is an amount effective to reduce its incidence in a treated population relative to an untreated control population.
  • the term "subject” may include mammals, preferably humans of any age suffering from pathological characteristics. Preferably, the term may also include individuals at risk of developing pathological characteristics.
  • the pharmaceutical combination comprises a therapeutic agent X, wherein the therapeutic agent X is selected from the group consisting of compounds of general formula (I) or pharmaceutically acceptable salts thereof.
  • the pharmaceutical composition is capable of promoting cell or tissue expansion or growth.
  • the pharmaceutical composition is capable of allowing cells or sustained expansion for at least 4 days, 5 days, 6 days, 8 days, 9 days, 10 days, 20 days, 30 days, 40 days, 50 days, 100 days days, 150 days, 200 days, 300 days, 400 days or even more days.
  • the pharmaceutical combinations may be used to prevent or treat cellular or tissue fibrosis.
  • the pharmaceutical combinations may be used with cells or tissues selected from cells or tissues derived from endoderm, ectoderm, mesoderm or germline.
  • the pharmaceutical combination can be used to prevent or treat aging-related diseases or symptoms selected from the group consisting of amyotrophy, cachexia, disuse atrophy, myopathy, alopecia cardiomyopathy, skin wrinkles, baldness, Macular degeneration, hepatic steatosis, steatohepatitis, type 2 diabetes (T2D), chronic obstructive pulmonary disease (COPD), osteoarthritis, osteoporosis, fibrosis, Alzheimer's disease, Parkinson's disease, dementia atherosclerosis sclerosis, cardiovascular disease, arthritis, rheumatoid arthritis, periodontitis, cataracts, osteoporosis, fibrosis, liver cirrhosis, idiopathic pulmonary fibrosis, cardiac fibrosis, Uterine fibrosis, scars, arthrofibrosis, chronic kidney disease, Crohn's disease, keloids, myelofibrosis, retroperitoneal fibrosis, scleroderma,
  • compositions of the present invention may be suitable for oral administration (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical administration (for example as a cream, ointment, gel, or aqueous or oily solution or suspension), by inhalation (for example as a finely divided powder or liquid aerosol), by insufflation (for example as a finely divided powder) or parenterally (for example as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular or intramuscular administration, or as suppositories for rectal administration).
  • oral administration for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs
  • topical administration for example as a cream, ointment
  • compositions of the present invention can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art.
  • suitable pharmaceutically acceptable excipients for tablet formulations include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate; granulating and disintegrating agents such as corn starch or alginic acid; binders , such as starch; lubricants, such as magnesium stearate, stearic acid, or talc; preservatives, such as ethyl or propyl paraben; and antioxidants, such as ascorbic acid.
  • Tablet preparations may be uncoated or coated, either to modify their disintegration in the gastrointestinal tract and subsequent absorption of the active ingredients, or to improve their stability and/or appearance, both of which In either case, conventional coating agents and methods well known in the art may be used.
  • the dosage and frequency of administration of the pharmaceutical composition of the present invention are not strictly limited and may vary according to many factors, such as age, weight, general health, diet, gender, drug to be administered, route of administration (or method) and treatment The seriousness of the condition and the judgment of the attending physician.
  • the pharmaceutical composition of the present invention can be administered once or more times a day, for example once a day, twice a day, three times a day or more, and can also be administered once every two days, once every three days, every three days. Administer once a week or other frequency.
  • a treatment course may include 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or longer.
  • therapeutic agent 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or longer.
  • the pharmaceutical combination is administered to an individual or subject over the age of 40.
  • the present invention provides a composition comprising a therapeutic agent X or a pharmaceutically acceptable salt thereof, wherein the therapeutic agent X is selected from a compound of general formula (I) or a pharmaceutically acceptable salt thereof.
  • the composition is capable of promoting cell or tissue expansion or growth.
  • the composition is capable of allowing cells or sustained expansion for at least 4 days, 5 days, 6 days, 8 days, 9 days, 10 days, 20 days, 30 days, 40 days, 50 days, 100 days , 150 days, 200 days, 300 days, 400 days or even more days.
  • the combination can be used to prevent or treat cellular or tissue fibrosis.
  • the combinations may be used with cells or tissues selected from cells or tissues derived from endoderm, ectoderm, mesoderm or germline.
  • the composition can be used to increase physical endurance.
  • compositions can be used to relieve fatigue. In some embodiments, the compositions can be used to relieve exercise fatigue.
  • compositions may be used for nutritional supplementation.
  • compositions may be used to improve appearance (eg, but not limited to, bodybuilding, wrinkle removal, hair growth, hair volume increase, hair loss prevention).
  • the compositions may be added to nutraceuticals, dietary supplements, sports drinks, or nutritional formulations.
  • the composition may be added to a health product, dietary supplement, sports drink, or nutritional formulation, wherein in the health product, dietary supplement, sports drink, or nutritional formulation, the composition
  • the proportion of ingredients does not exceed 99.9%, 99.5%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 97% , 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70 %, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, 49%, 48%, 47%, 46%, 45%,
  • the composition can be added to a protein source or food. in some In embodiments, the composition can be added to a protein source or food, wherein the proportion of ingredients of the composition in the protein source or food is no more than 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50% ,49%,48%,47%,46%,45%,44%,43%,42%,41%,40%,39%,38%,37%,36%,35%,34%,33 %, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15% 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 61%, 60%
  • the composition may be added to cosmetics, nutraceuticals or cosmeceuticals.
  • the compositions can be used to improve appearance.
  • the composition can be added to cosmetics, health cosmetics or cosmeceuticals, wherein, in the cosmetics, In health care cosmetics or cosmeceuticals, the proportion of ingredients of the composition is no more than 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89% , 88%, 97%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72 %, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 5
  • compositions of the present invention may be suitable for oral administration (for example, but not limited to, as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups, food products, or elixir), topically (for example as a cream, ointment, gel, or aqueous or oily solution or suspension), administration by inhalation (for example as a finely divided powder or liquid aerosol), administration by insufflation (for example as a finely divided powder) or for parenteral administration (eg as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular or intramuscular administration, or as suppositories for rectal administration).
  • oral administration for example, but not limited to, as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups, food products, or
  • the composition can be added to a health product, dietary supplement, sports drink or nutritional formulation, wherein the amount of therapeutic agent X can range from 0.1 mg to 5000 mg per day in terms of daily dosage, or Preferably, it is 10 mg to 5000 mg, more preferably 100 mg to 5000 mg, or even more preferably 100 mg to 5000 mg. Therefore, the above dosage can be reasonably achieved according to the above different application frequencies and methods.
  • the nutraceutical, dietary supplement, sports drink or nutritional formulation comprising the combination may be taken once, twice, three or more times daily.
  • the nutraceutical, dietary supplement, sports drink or nutritional formulation comprising the combination can be taken once daily, every two days, every three days, every four days, every five days, or once a week , two, three or more times.
  • the nutraceutical, dietary supplement, sports drink or nutritional preparation is presented in a form selected from the group consisting of pills, tablets, capsules, softgels, chewing gum, lozenges, beverages or powder mixtures.
  • the composition may be added to a protein source or food, wherein in terms of daily dosage, the amount of therapeutic agent to 10000 mg, or even more preferably 100 mg to 10000 mg. Therefore, the above dosage can be reasonably achieved according to the above different application frequencies and methods.
  • the protein source or food containing the combination may be taken once, twice, three or more times daily.
  • the nutraceutical, dietary supplement, sports drink or nutritional formulation comprising the combination can be taken once daily, every two days, every three days, every four days, every five days, or once a week , two, three or more times.
  • the protein or food may be liquid or solid.
  • the protein or food is selected from, but is not limited to, milk, dairy products, artificial milk products, meat, meat products, artificial meat products, beverages, eggs, egg products, artificial egg products, candy, cereals, cereals products, snacks, desserts, protein bars, shakes, plant proteins, microbial proteins, synthetic proteins, whey proteins, rice products, wheat products, vegetable products, fruit products, soups, salads or processed foods.
  • the composition may be added to cosmetics, nutraceuticals or cosmeceuticals , wherein in terms of daily dosage, the amount of therapeutic agent The application frequency and method should be used to reasonably achieve the above dosage.
  • the cosmetic, nutraceutical or cosmeceutical is suitable for topical application.
  • the cosmetic, nutraceutical, or cosmeceutical may be solid or liquid.
  • the cosmetic, nutraceutical or cosmeceutical is selected from, but not limited to, creams, ointments, gels, lotions, soaps, facial masks, body masks, patches or aqueous or oily solutions or suspensions.
  • HSKM muscle stem cells in the 15th to 20th generations are on the edge of aging. They have not yet aged, but their proliferation and differentiation capabilities have begun to decline compared with cells in earlier generations.
  • HSKM muscle stem cells were seeded into a 6-well plate covered with gelatin (Matrigel TM , Corning, USA) at 6 ⁇ 10 4 cells per well, and 0, 50, 100, and 200 ⁇ M therapeutic agent X (general formula I) Processing of HSKM muscle stem cells.
  • the effect of therapeutic agent X (general formula I) on cell morphology was observed under a microscope (Nikon TS2, Japan) every day.
  • therapeutic agent X (general formula I) at 100-200 ⁇ M significantly increased the cell proliferation rate. It can be seen that therapeutic agent X (general formula I) has a linear effect on the morphology of stem cells and the proliferation number of stem cells. Effect, 100-200 ⁇ M especially significantly promotes the stemness of HSKM muscle stem cells and promotes stem cell proliferation.
  • TWIST2 is a gene that maintains stemness.
  • TWIST2+ myogenic progenitor cells can differentiate to form type IIb/x muscle fibers during skeletal muscle regeneration, so TWIST2 is one of the markers of stemness (Liu et al., 2017); expression of MYH3 It is related to the differentiation of muscle stem cells and is a terminal differentiation marker in the muscle embryonic stage and early muscle regeneration (Liu et al., 2017).
  • Therapeutic Agent X (Formula II). After counting, HSKM muscle stem cells were seeded into a 6-well plate covered with gelatin (Matrigel TM , Corning, USA) at 6 ⁇ 10 4 cells per well, and 0, 0.1, 1, 10, 100, and 1000 ⁇ M therapeutic agents were used. X (general formula II) treats HSKM muscle stem cells. After 4 days of drug treatment, the effect of therapeutic agent X (general formula II) on cell morphology was observed under a microscope (Nikon TS2, Japan). The results showed that as the drug concentration increased, the cell morphology changed significantly ( Figure 5). At 100 ⁇ M, bulk cells became more oval and cell mass increased significantly. At 1000 ⁇ M, bulk cells became more elongated and cell mass was significantly reduced. Therefore, we verified that 100 ⁇ M therapeutic agent X (general formula II) has the best effect on maintaining the stemness of muscle stem cells.
  • both the control group and the test group of the present invention adopt intraperitoneal injection.
  • the injection volume starts at 4 ⁇ l/g body weight and is adjusted according to the dosage, in which the therapeutic agent X in the test group is diluted in PBS (Gibco, USA)
  • the dosage is between 0.3 mg/kg and 120 mg/kg body weight, while in the control group, only the same amount of solvent is usually used as a placebo.
  • any combination of various embodiments of the present invention can also be carried out. As long as they do not violate the idea of the present invention, they should also be regarded as the disclosed content of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一种用于抵抗衰老的组合物及其用途或方法。药物组合物包含治疗剂X或其药学上可接受的盐以及至少一种药学上可接受的赋形剂，其中，治疗剂X选自通式I和通式II化合物或其药学上可接受的盐。药物组合物可以有效让细胞或组织抵抗衰老、年轻化，并治疗或预防衰老相关的疾病或症状。

Description

一种用于抵抗衰老的组合物及其用途或方法
相关申请的引用
本发明要求2022年07月14日在中国提交的，名称为“一种用于抵抗衰老的组合物及其用途或方法”、申请号为202210829713.3的发明专利申请的优先权，通过引用的方式将上述专利申请的全部内容并入本文。
技术领域
本发明涉及小分子化合物领域，具体地，涉及一种用于抵抗衰老的组合物及其用途。
背景技术
衰老与组织的进行性退化有关，这对重要器官的结构和功能有负面影响，是大多数慢性病最重要的已知危险因素之一。鉴于世界上60岁以上人口的比例将在未来40年内翻倍，与年龄相关的慢性疾病发病率的增加将给医疗资源带来巨大负担。衰老的特点是损伤的逐渐累积，导致生理完整性的丧失、功能受损和死亡的脆弱性增加。
发明内容
本发明的目的在于克服现有技术中存在的缺陷，即市面上的所有药物都不能很好地有效治疗或预防衰老。本申请的发明人经过大量实验和反复摸索，发现了一种用于抵抗衰老的组合物。
在第一方面，本发明提供了一种药物组合物，其包含治疗剂X或其药学上可接受的盐，其中，所述治疗剂X选自通式(I)或通式(II)化合物或其药学上可接受的盐。
在一些实施方案中，所述药物组合物能够促进细胞或组织扩增或增长。
在一些实施方案中，所述药物组合物能够让细胞或持续扩增至少4天、5天、6天、8天、9天、10天、20天、30天、40天、50天、100天、150天、200天、300天、400天或甚至更多天。
在一些实施方案中，所述药物组合可用于预防或治疗细胞或组织纤维化。
在一些实施方案中，所述药物组合可用于的细胞或组织选自源自内胚层、外胚层、中胚层或生殖细胞或组织。
在一个实施方式中，所述药物组合可用于预防或治疗衰老相关的疾病或症状，所述衰老疾病选自肌萎缩、恶病质、废用性萎缩、肌病、脱发心肌病、皮肤皱纹、秃顶、黄斑变性、肝脂肪变性、脂肪性肝炎、2型糖尿病(T2D)、慢性阻塞性肺病(COPD)、骨关节炎、骨质疏松、纤维化、阿尔茨海默病、帕金森病、痴呆动脉粥样硬化、心血管疾病、关节炎、类风湿性关节炎、，牙周炎、白内障、骨质疏松、纤维化、肝硬化、特发性肺纤维化、心脏纤维 化、子宫纤维化、瘢痕、关节纤维化、慢性肾病、克罗恩病、瘢痕疙瘩、骨髓纤维化、腹膜后纤维化、硬皮病、硬化、慢性伤口(如糖尿病足溃疡)、慢性皮肤纤维化、皮肤纤维化、皮肤老化、，非酒精性脂肪性肝炎(NASH)、脱发、组织萎缩、更年期、卵巢老化、原发性卵巢功能不全、子宫内膜增生、子宫腺肌病和肌萎缩、神经退行性疾病以及任何其他由损伤、手术、癌症、先天性、发育性和环境组织损失或损伤引起的疾病。
在一些实施方案中，所述药物组合施用于40岁以上的个人或受试者。
在第二方面，本发明提供了一种组合物，其包含治疗剂X或其药学上可接受的盐，其中，所述治疗剂X选自通式(I)或通式(II)化合物或其药学上可接受的盐。
在一些实施方案中，所述组合物能够促进细胞或组织扩增或增长。
在一些实施方案中，所述组合物能够让细胞或持续扩增至少4天、5天、6天、8天、9天、10天、20天、30天、40天、50天、100天、150天、200天、300天、400天或甚至更多天。
在一些实施方案中，所述组合可用于预防或治疗细胞或组织纤维化。
在一些实施方案中，所述组合可用于的细胞或组织选自源自内胚层、外胚层、中胚层或生殖细胞或组织。
在一些实施方案中，所述组合物可用于提高身体耐力。
在一些实施方案中，所述组合物可用于缓解疲劳。在一些实施方案中，所述组合物可用于缓解运动疲劳。
在一些实施方案中，所述组合物可用用于补充营养。
在一些实施方案中，所述组合物可用于改善外观(例如但不限于健美、去皱纹、育发、增加发量、防止脱发)。
在一些实施方案中，所述组合物可被添加到保健品、膳食补充剂、运动饮料或营养制剂中。在一些实施方案中，所述组合物可添加到保健品、膳食补充剂、运动饮料或营养制剂中，其中，在所述保健品、膳食补充剂、运动饮料或营养制剂中，所述组合物的成分比例不多于99.9％、99.5％、99％、98％、97％、96％、95％、94％、93％、92％、91％、90％、89％、88％、97％、86％、85％、84％、83％、82％、81％、80％、79％、78％、77％、76％、75％、74％、73％、72％、71％、70％、69％、68％、67％、66％、65％、64％、63％、62％、61％、60％、59％、58％、57％、56％、55％、54％、53％、52％、51％、50％、49％、48％、47％、46％、45％、44％、43％、42％、41％、40％、39％、38％、37％、36％、35％、34％、33％、32％、31％、30％、29％、28％、27％、26％、25％、24％、23％、22％、21％、20％、19％、18％、17％、16％、15％14％、13％、12％、11％、10％、9％、8％、7％、6％、5％、4％、3％、2％、1％、0.9％、0.8％、0.7％、0.6％、0.5％、0.4％、0.3％、0.2％、0.1％或甚至更少。在一些实施方案中，包含所述组合物的保健品、膳食补充剂、运动饮料或营养制剂施用于40岁以上的个人或受试者。
在一些实施方案中，所述组合物可被添加到蛋白质源或食物中。在一些实施方案中，所述组合物可添加到蛋白质源或食物中，其中，在所述蛋白质源或食物中，所述组合物的成分比例不多于70％、69％、68％、67％、66％、65％、64％、63％、62％、61％、60％、59％、58％、57％、56％、55％、54％、53％、52％、51％、50％、49％、48％、47％、46％、45％、44％、43％、42％、 41％、40％、39％、38％、37％、36％、35％、34％、33％、32％、31％、30％、29％、28％、27％、26％、25％、24％、23％、22％、21％、20％、19％、18％、17％、16％、15％14％、13％、12％、11％、10％、9％、8％、7％、6％、5％、4％、3％、2％、1％、0.9％、0.8％、0.7％、0.6％、0.5％、0.4％、0.3％、0.2％、0.1％或甚至更少。在一些实施方案中，包含所述组合物的蛋白质或食物施用于40岁以上的个人或受试者。
在一些实施方案中，所述组合物可添加到化妆品、保健化妆品或药妆品中。在一些实施方案中，所述组合物可添加到化妆品、保健化妆品或药妆品中，其中，在所述化妆品、保健化妆品或药妆品中，所述组合物的成分比例不多于99％、98％、97％、96％、95％、94％、93％、92％、91％、90％、89％、88％、97％、86％、85％、84％、83％、82％、81％、80％、79％、78％、77％、76％、75％、74％、73％、72％、71％、70％、69％、68％、67％、66％、65％、64％、63％、62％、61％、60％、59％、58％、57％、56％、55％、54％、53％、52％、51％、50％、49％、48％、47％、46％、45％、44％、43％、42％、41％、40％、39％、38％、37％、36％、35％、34％、33％、32％、31％、30％、29％、28％、27％、26％、25％、24％、23％、22％、21％、20％、19％、18％、17％、16％、15％14％、13％、12％、11％、10％、9％、8％、7％、6％、5％、4％、3％、2％、1％、0.9％、0.8％、0.7％、0.6％、0.5％、0.4％、0.3％、0.2％、0.1％或甚至更少。在一些实施方案中，包含所述组合物的化妆品、保健化妆品或药妆品施用于40岁以上的个人或受试者。
附图说明
附图是用来提供对本发明的进一步理解，并且构成说明书的一部分，与下面的具体实施方式一起用于解释本发明，但并不构成对本发明的限制。在附图中：
图1示出了与单独使用二甲基亚砜载体对照(Ctrl)相比，用不同浓度的治疗剂X(通式I)的钠加盐溶解在二甲基亚砜载体对照(Ctrl)中处理衰老的人骨骼肌(Hskm)细胞。100-200μM治疗剂X(通式I)的钠加盐能显著促进骨骼肌细胞增殖。图中的cholate指的是治疗剂X(通式I)的钠加盐。
图2示出了与二甲基亚砜载体对照组相比，用不同浓度的治疗剂X(通式I)的钠加盐处理2天后，衰老的骨骼肌细胞的增殖率(相对于第0天的倍数变化)。100-200μM治疗剂X(通式I)的钠加盐能显著增加骨骼肌细胞的增殖率。图中的cholate指的是治疗剂X(通式I)的钠加盐。
图3示出了与二甲基亚砜载体对照组相比，用不同浓度的治疗剂X(通式I)的钠加盐处理4天后，衰老的骨骼肌细胞的增殖率(相对于第0天的倍数变化)。100-200μM治疗剂X(通式I)的钠加盐能显著增加骨骼肌细胞的增殖率。图中的cholate指的是治疗剂X(通式I)的钠加盐。
图4示出不同浓度治疗剂X(通式II)处理4天后骨骼肌细胞的肌源性基因表达状态。图中的Twist2和Myh3都是肌源性基因，而GAPDH是管家基因，用于对标与量化肌源性基因的表达。Myh3水平表明，100μM治疗剂X(通式II)可降低骨骼肌细胞的终末分化。1mM则太高，促进了终末分化。
图5示与二甲基亚砜载体对照组(对照组)相比，用不同浓度的治疗剂X(通式II)处理骨骼肌细胞。100μM治疗剂X(通式II)显著增加骨骼肌细胞增殖。
图6示与二甲基亚砜载体对照组(con)相比，用不同浓度的治疗剂X(通式II)处理4天后，骨骼肌细胞的增殖率。100μM治疗剂X(通式II)显著增加骨骼肌细胞增殖。
具体实施方式
以下对本发明的具体实施方式进行详细说明。应当理解的是，此处所描述的具体实施方式仅用于说明和解释本发明，并不用于限制本发明。
在本文中所披露的范围的端点和任何值都不限于该精确的范围或值，这些范围或值应当理解为包含接近这些范围或值的值。对于数值范围来说，各个范围的端点值之间、各个范围的端点值和单独的点值之间，以及单独的点值之间可以彼此组合而得到一个或多个新的数值范围，这些数值范围应被视为在本文中具体公开。
抵抗衰老的药物组合物和其用途(或方法)
在一个方面，本发明提供了一种用于抵抗衰老药物组合物，其包含治疗剂X或其药学上可接受的盐。
术语“药学上可接受的”是指在合理的医学判断范围内、适合用于与人类和动物的组织接触而没有过度的毒性、刺激性、变态反应或其它问题或并发症、与合理的利益/风险比相称的那些化合物、材料、组合物和/或剂型。治疗剂X可以形成稳定的药学上可接受的酸或碱盐，并且在这样的情况下，施用作为盐的化合物可能是恰当的。
在一个实施方式中，所述药物组合物中的治疗剂X可以以治疗有效量存在。如本文所用，术语“治疗有效量”是指化合物或组合物的量足以显著且正性地改变待治疗的症状和/或病情(例如提供正性临床反应)。用于药物组合物中的活性成分的有效量将随所治疗的特定病情、病情的严重程度、治疗的持续时间、同时疗法的性质、所采用的特定活性成分、所利用的特定可药用赋形剂、以及主治医师的知识和专业知识内的类似因素而变化。
如本文所用，术语“治疗”是指用于获得有益或期望的临床结果的方法。术语“治疗”是指抑制、预防或阻止病理(疾病、障碍或病症)的发展或进展和/或引起病理的减轻、缓解或消退。本领域技术人员将理解，可以使用各种方法和测定来评估病理学的发展，并且类似地，可以使用各种方法和测定来评估病理学的减轻、缓解或消退。
如本文所用，术语“预防”是指防止疾病、障碍或病症在可能有疾病风险但尚未被诊断为患有该疾病的受试者中发生。在人口研究中可以证明预防(以及有效预防的剂量)。例如，相对于未治疗的对照人口，预防给定疾病或医学病症的有效量是减少治疗人口中发生率的有效量。
如本文所用，术语“受试者”可以包括哺乳动物，优选患有病理特征的任何年龄的人。优选地，该术语还可以包括有发展病理特征风险的个体。
根据本发明，所述药物组合包含治疗剂X，其中所述治疗剂X选自通式(I)化合物或其药学上可接受的盐。
在一些实施方案中，所述药物组合物能够促进细胞或组织扩增或增长。
在一些实施方案中，所述药物组合物能够让细胞或持续扩增至少4天、5天、6天、8天、9天、10天、20天、30天、40天、50天、100天、150天、200天、300天、400天或甚至更多天。
在一些实施方案中，所述药物组合可用于预防或治疗细胞或组织纤维化。
在一些实施方案中，所述药物组合可用于的细胞或组织选自源自内胚层、外胚层、中胚层或生殖细胞或组织。
在一个实施方式中，所述药物组合可用于预防或治疗衰老相关的疾病或症状，所述衰老疾病选自肌萎缩、恶病质、废用性萎缩、肌病、脱发心肌病、皮肤皱纹、秃顶、黄斑变性、肝脂肪变性、脂肪性肝炎、2型糖尿病(T2D)、慢性阻塞性肺病(COPD)、骨关节炎、骨质疏松、纤维化、阿尔茨海默病、帕金森病、痴呆动脉粥样硬化、心血管疾病、关节炎、类风湿性关节炎、牙周炎、白内障、骨质疏松、纤维化、肝硬化、特发性肺纤维化、心脏纤维化、 子宫纤维化、瘢痕、关节纤维化、慢性肾病、克罗恩病、瘢痕疙瘩、骨髓纤维化、腹膜后纤维化、硬皮病、硬化、慢性伤口(如糖尿病足溃疡)、慢性皮肤纤维化、皮肤纤维化、皮肤老化、皱纹、非酒精性脂肪性肝炎(NASH)、脱发、组织萎缩、更年期、卵巢老化、原发性卵巢功能不全、子宫内膜增生、子宫腺肌病和肌萎缩、神经退行性疾病以及任何其他由损伤、手术、癌症、先天性、发育性和环境组织损失或损伤引起的疾病。
施用方式
本发明的药物组合物可以是适合于口服施用(例如作为片剂，锭剂，硬或软胶囊，水性或油性悬液，乳液，可分散的粉末或颗粒，糖浆或酏剂)、局部施用(例如作为乳膏，软膏，凝胶，或水性或油性溶液或悬液)、通过吸入施用(例如作为细碎粉末或液体气溶胶)、通过吹入施用(例如作为细碎粉末)或肠胃外施用(例如作为用于静脉内、皮下、肌内或肌肉内施用的无菌水性或油性溶液，或作为用于直肠施用的栓剂)的形式。
本发明的药物组合物可通过常规程序使用本领域公知的常规药物赋形剂获得。用于片剂制剂的合适的可药用赋形剂包括，例如惰性稀释剂，如乳糖、碳酸钠、磷酸钙或碳酸钙；造粒和崩解剂，如玉米淀粉或藻酸；粘合剂，如淀粉；润滑剂，如硬脂酸镁、硬脂酸或滑石；防腐剂，如对羟基苯甲酸乙酯或丙酯；和抗氧化剂，如抗坏血酸。片剂制剂可以是未包衣的或包衣的，包衣或是为了修改它们在胃肠道内的崩解和随后的活性成分吸收，或是为了改善它们的稳定性和/或外观，这两种情况下都可以使用本领域公知的常规包衣剂和方法。
本发明的药物组合物在施用剂量和频率方面没有严格的限制，可以根据许多因素而变化，例如年龄、体重、总体健康、饮食、性别、待施用药物、施用途(或方法)径和所治疗病症的严重性以及主治医师的判断。在一般情况下，本发明的药物组合物可以以每天一次或多次施用，例如每天一次，每天两次，每天三次或更多，并且，也可以以每两天一次，每三天一次，每周一次或其它的频率施用。就每日剂量而言，治疗剂X的量可以为每天0.1mg至5000mg，或优选10mg至1000mg，更优选100mg至1000mg，或甚至更优选100mg至500mg，治疗剂B的量可以为每天0.1mg至1000mg，或优选 10mg至1000mg，更优选100mg至1000mg，或甚至更优选30mg至180mg，因此，可以根据上述不同的施用频率和方式来合理达到上述用量的施用，例如每天一次施用5mg至500mg的治疗剂A，或每天两次施用10mg至250mg的治疗剂X等。
在一些实施方案中，治疗疗程可包括1天、2天、3天、4天、5天、6天、7天、2周、3周、1个月、2个月、3个月、4个月、5个月、6个月、7个月、8个月、9个月、10个月、11个月、12个月或更长。在一些实施例中，治疗剂X可按每天一次，每天两次，每天三次或更多，并且，也可以以每两天一次，每三天一次，每周一次或其它的频率施用。
在一些实施方案中，所述药物组合施用于40岁以上的个人或受试者。
用于促进细胞或组织健康的组合物和其用途(或方法)
本发明提供了一种组合物，其包含治疗剂X或其药学上可接受的盐，其中，所述治疗剂X选自通式(I)化合物或其药学上可接受的盐。
在一些实施方案中，所述组合物能够促进细胞或组织扩增或增长。
在一些实施方案中，所述组合物能够让细胞或持续扩增至少4天、5天、6天、8天、9天、10天、20天、30天、40天、50天、100天、150天、200天、300天、400天或甚至更多天。
在一些实施方案中，所述组合可用于预防或治疗细胞或组织纤维化。
在一些实施方案中，所述组合可用于的细胞或组织选自源自内胚层、外胚层、中胚层或生殖细胞或组织。
在一些实施方案中，所述组合物可用于提高身体耐力。
在一些实施方案中，所述组合物可用于缓解疲劳。在一些实施方案中，所述组合物可用于缓解运动疲劳。
在一些实施方案中，所述组合物可用用于补充营养。
在一些实施方案中，所述组合物可用于改善外观(例如但不限于健美、去皱纹、育发、增加发量、防止脱发)。
在一些实施方案中，所述组合物可被添加到保健品、膳食补充剂、运动饮料或营养制剂中。在一些实施方案中，所述组合物可添加到保健品、膳食补充剂、运动饮料或营养制剂中，其中，在所述保健品、膳食补充剂、运动饮料或营养制剂中，所述组合物的成分比例不多于99.9％、99.5％、99％、98％、97％、96％、95％、94％、93％、92％、91％、90％、89％、88％、97％、86％、85％、84％、83％、82％、81％、80％、79％、78％、77％、76％、75％、74％、73％、72％、71％、70％、69％、68％、67％、66％、65％、64％、63％、62％、61％、60％、59％、58％、57％、56％、55％、54％、53％、52％、51％、50％、49％、48％、47％、46％、45％、44％、43％、42％、41％、40％、39％、38％、37％、36％、35％、34％、33％、32％、31％、30％、29％、28％、27％、26％、25％、24％、23％、22％、21％、20％、19％、18％、17％、16％、15％14％、13％、12％、11％、10％、9％、8％、7％、6％、5％、4％、3％、2％、1％、0.9％、0.8％、0.7％、0.6％、0.5％、0.4％、0.3％、0.2％、0.1％或甚至更少。在一些实施方案中，包含所述组合物的保健品、膳食补充剂、运动饮料或营养制剂施用于40岁以上的个人或受试者。
在一些实施方案中，所述组合物可被添加到蛋白质源或食物中。在一些 实施方案中，所述组合物可添加到蛋白质源或食物中，其中，在所述蛋白质源或食物中，所述组合物的成分比例不多于70％、69％、68％、67％、66％、65％、64％、63％、62％、61％、60％、59％、58％、57％、56％、55％、54％、53％、52％、51％、50％、49％、48％、47％、46％、45％、44％、43％、42％、41％、40％、39％、38％、37％、36％、35％、34％、33％、32％、31％、30％、29％、28％、27％、26％、25％、24％、23％、22％、21％、20％、19％、18％、17％、16％、15％14％、13％、12％、11％、10％、9％、8％、7％、6％、5％、4％、3％、2％、1％、0.9％、0.8％、0.7％、0.6％、0.5％、0.4％、0.3％、0.2％、0.1％或甚至更少。在一些实施方案中，包含所述组合物的蛋白质或食物施用于40岁以上的个人或受试者。
在一些实施方案中，所述组合物可添加到化妆品、保健化妆品或药妆品中。在一些实施方案中，所述组合物可用于改善外观。(例如但不限于健美、去皱纹、育发、增加发量或防止脱发)在一些实施方案中，所述组合物可添加到化妆品、保健化妆品或药妆品中，其中，在所述化妆品、保健化妆品或药妆品中，所述组合物的成分比例不多于99％、98％、97％、96％、95％、94％、93％、92％、91％、90％、89％、88％、97％、86％、85％、84％、83％、82％、81％、80％、79％、78％、77％、76％、75％、74％、73％、72％、71％、70％、69％、68％、67％、66％、65％、64％、63％、62％、61％、60％、59％、58％、57％、56％、55％、54％、53％、52％、51％、50％、49％、48％、47％、46％、45％、44％、43％、42％、41％、40％、39％、38％、37％、36％、35％、34％、33％、32％、31％、30％、29％、28％、27％、26％、25％、24％、23％、22％、21％、20％、19％、18％、17％、16％、15％14％、13％、12％、11％、10％、9％、8％、7％、6％、5％、4％、3％、2％、1％、0.9％、0.8％、0.7％、0.6％、0.5％、0.4％、0.3％、0.2％、0.1％或甚至更少。在一些实施方案中，包含所述组合物的化妆品、保健化妆品或药妆品施用于40岁以上的个人或受试者。
施用方式
本发明的组合物可以是适合于口服施用(例如但不限于作为片剂，锭剂，硬或软胶囊，水性或油性悬液，乳液，可分散的粉末或颗粒，糖浆，食品， 或酏剂)、局部施用(例如作为乳膏，软膏，凝胶，或水性或油性溶液或悬液)、通过吸入施用(例如作为细碎粉末或液体气溶胶)、通过吹入施用(例如作为细碎粉末)或肠胃外施用(例如作为用于静脉内、皮下、肌内或肌肉内施用的无菌水性或油性溶液，或作为用于直肠施用的栓剂)的形式。
在一些实施方案中，所述组合物可被添加于保健品、膳食补充剂、运动饮料或营养制剂中，其中就每日剂量而言，治疗剂X的量可以为每天0.1mg至5000mg，或优选10mg至5000mg，更优选100mg至5000mg，或甚至更优选100mg至5000mg，因此，可以根据上述不同的施用频率和方式来合理达到上述用量的施用。在某些实施方案中，包含所述组合的所述保健品、膳食补充剂、运动饮料或营养制剂每日可服用一次、两次、三次或更多次。在某些实施方案中，包含所述组合的所述保健品、膳食补充剂、运动饮料或营养制剂每日、每两日、每三日、每四日、每5日或每周可服用一次、两次、三次或更多次。在一些实施方案中，所述保健品、膳食补充剂、运动饮料或营养制剂所呈现的形式选自药丸、片剂、胶囊、软胶囊、口香糖、含片、饮料或粉末混合物。
在一些实施方案中，所述组合物可被添加于蛋白质源或食物中，其中就每日剂量而言，治疗剂X的量可以为每天0.1mg至10000mg，或优选10mg至10000mg，更优选100mg至10000mg，或甚至更优选100mg至10000mg，因此，可以根据上述不同的施用频率和方式来合理达到上述用量的施用。在某些实施方案中，包含所述组合的所述蛋白质源或食物每日可服用一次、两次、三次或更多次。在某些实施方案中，包含所述组合的所述保健品、膳食补充剂、运动饮料或营养制剂每日、每两日、每三日、每四日、每5日或每周可服用一次、两次、三次或更多次。在一些实施方案中，所述蛋白质或食物可以是液体或固体。在一些实施方案中，所述蛋白质或食物选自但不限于牛奶、奶制品、人造奶制品、肉、肉制品、人造肉制品、饮料、鸡蛋、蛋制品、人造蛋制品、糖果、谷物、谷物制品、零食、甜点、蛋白质棒、奶昔、植物蛋白、微生物蛋白、合成蛋白、乳清蛋白、大米制品、小麦制品、蔬菜制品、水果制品、汤、沙拉或加工食品。
在一些实施方案中，所述组合物可添加到化妆品、保健化妆品或药妆品 中，其中就每日剂量而言，治疗剂X的量可以为每天0.1mg至10000mg，或优选10mg至10000mg，更优选100mg至10000mg，或甚至更优选100mg至10000mg，因此，可以根据上述不同的施用频率和方式来合理达到上述用量的施用。在某些实施方案中，所述化妆品、保健化妆品或药妆品适合于局部施用。在某些实施方案中，所述化妆品、保健化妆品或药妆品可以是固体或液体。在某些实施方案中，所述化妆品、保健化妆品或药妆品选自但不限于乳膏、软膏、凝胶、乳液、肥皂、面膜、身体面膜、贴片或水性或油性溶液或悬液。
以下将通过实施例对本发明进行详细描述。
实施例
为了验证治疗剂X在体外对骨骼肌细胞的影响，我们首先检测了不同浓度的治疗剂X(通式I)对细胞形态的作用。第15-20代的HSKM肌肉干细胞处于衰老的边缘，还未衰老但增殖和分化能力相比于早代次的细胞，已经开始下降。HSKM肌肉干细胞在计数后，按每孔6x 104个细胞接种到铺好明胶(MatrigelTM,Corning,美国)的6孔板中，并使用0、50、100、200μM的治疗剂X(通式I)处理HSKM肌肉干细胞。药物处理的4天内，每天在显微镜(Nikon TS2,日本)下观察治疗剂X(通式I)对细胞形态的影响。
结果显示，随着药物浓度的增加，细胞形态发生明显变化(图1)。第二天观察细胞，发现均无显著变化。观察第四天，与等量的DMSO(Sigma,美国)溶剂对照组相比，50μM治疗剂X(通式I)处理的细胞形态改变虽不显著，但100μM治疗剂X(通式I)使大部分细胞形态开始变椭圆，有抵抗终末分化的趋势；200μM治疗剂X(通式I)处理细胞约80-90％的细胞明显变椭圆，细胞保持肌肉干细胞形态，细胞量也明显增加了。从细胞形态来看，高浓度治疗剂X(通式I)有促进HSKM肌肉干细胞干性的作用。
随后我们对每孔HSKM肌肉干细胞的增殖能力进行了统计(ImageJ,NIH，美国)，并计算与初始接种细胞数量的差异倍数(图2，图3)。我们发现，低浓度的治疗剂X(通式I)也即50μM相比于对照组，对细胞总数影响相对较小。100-200μM的治疗剂X(通式I)则显著提升了细胞增殖率。由此可见，治疗剂X(通式I)对干细胞的形态和干细胞的增殖数量有线性 作用，100-200μM尤其显著促进HSKM肌肉干细胞的干性，并且促进干细胞增殖。
根据上述结果，我们从基因表达水平层面，验证治疗剂X对骨骼肌细胞的干性和分化的作用。
治疗剂X(通式I)以线性形式导致HSKM肌肉干细胞的增殖率发生改变，可能是影响细胞的干性和分化潜能。因此我们检测了TWIST2以及MYH3两个基因在RNA水平的表达量，来验证治疗剂X是否影响HSKM肌肉干细胞的干性和分化。TWIST2是干性维持的基因，TWIST2+肌源性祖细胞在骨骼肌再生期间能分化形成IIb/x型肌纤维，因此TWIST2是干性的标记物之一(Liu et al.，2017)；MYH3的表达与肌肉干细胞的分化相关，是肌肉胚胎期和肌肉再生早期的终末分化标记物(Liu et al.，2017)。经过多轮的药物优化与检测后，基于逆转录酶(Takara,日本)的实时荧光定量qRT-PCR(Roche，美国)结果显示，100μM治疗剂X(通式II)略微抑制了HSKM肌肉干细胞TWIST2的表达，但显著抑制了MYH3基因的表达。1mM治疗剂X(通式II)则太高了，效果相反，TWIST2基因的表达量显著降低，MYH3基因的表达则显著升高(图4)。结果表明，100μM治疗剂X(通式II)最有效地促进了HSKM肌肉干细胞的干性维持，抑制了HSKM肌肉干细胞的分化。
我们进一步验证了治疗剂X(通式II)的功效。HSKM肌肉干细胞在计数后，按每孔6x 104个细胞接种到铺好明胶(MatrigelTM,Corning,美国)的6孔板中，并使用0、0.1、1、10、100、1000μM的治疗剂X(通式II)处理HSKM肌肉干细胞。药物处理4天后，显微镜(Nikon TS2,日本)下观察治疗剂X(通式II)对细胞形态的影响。结果显示，随着药物浓度的增加，细胞形态发生明显变化(图5)。在100μM，大量细胞变得更加椭圆，细胞量也显著增加。在1000μM，大量细胞变得更加细长，细胞量也显著降低。因此，我们验证了100μM治疗剂X(通式II)对于肌肉干细胞的干性维持有最佳效果。
此外，我们还进一步在动物体内验证了药物功效。在以下实施例中，所有动物(例如小鼠)程序均基于机构动物护理和使用委员会批准的动物护理指南。对于组织学，将组织样品固定在10％缓冲的福尔马林或Bouin溶液中 并包埋在石蜡中。本发明的对照组和试验组在实施例中均采用腹膜内注射，注射体积以4μl/g体重开始，并根据剂量调整，其中使得试验组中的治疗剂X在PBS(Gibco,美国)中稀释为剂量在0.3mg/kg至120mg/kg体重之间，而对照组中通常仅使用等量溶剂作为安慰剂。
对于各图表中的结果，数据表示为平均值±均方误差(SEM)，并且使用Student's t-检验(双尾分布，双样本不等方差)用于计算p值。统计显著性显示为p>0.05(无意义，n.s.)，p<0.05(一个星号，即*)、或p<0.01(两个星号，即**)、或p<0.001(三个星号，即***)。使用Microsoft Excel执行测试，其中测试类型始终设置为双样本等方差。结果显示，100μM治疗剂X能极其显著提升小鼠体重和肌肉质量，并且提升体内骨骼肌的肌肉细胞数量，抵抗肌肉萎缩与衰老。
以上详细描述了本发明的优选实施方式，但是，本发明并不限于上述实施方式中的具体细节，在本发明的技术构思范围内，可以对本发明的技术方案进行多种简单变型，这些简单变型均属于本发明的保护范围。
另外需要说明的是，在上述具体实施方式中所描述的各个具体技术特征，在不矛盾的情况下，可以通过任何合适的方式进行组合，为了避免不必要的重复，本发明对各种可能的组合方式不再另行说明。
此外，本发明的各种不同的实施方式之间也可以进行任意组合，只要其不违背本发明的思想，其同样应当视为本发明所公开的内容。

Claims (13)

  1. 一种用于抵抗细胞或组织衰老的药物组合物，其包含治疗剂X或其药学上可接受的盐；其中，所述治疗剂X选自通式(I)化合物或其药学上可接受的盐，
  2. 权利要求1所述的药物组合物，其中，所述药物组合物能够促进细胞或组织扩增或增长。
  3. 权利要求1和2所述的药物组合物，其中，所述药物组合物能够让细胞或持续扩增至少4天、5天、6天、8天、9天、10天、20天、30天、40天、50天、100天、150天、200天、300天、400天或甚至更多天。
  4. 权利要求1-3所述药物组合，其中，所述药物组合可用于预防或治疗细胞或组织纤维化。
  5. 权利要求1-4所述的药物组合物，其中，所述药物组合可用于预防或治疗衰老相关的疾病或症状，所述衰老疾病选自肌萎缩、恶病质、废用性萎缩、肌病、脱发心肌病、皮肤皱纹、秃顶、黄斑变性、肝脂肪变性、脂肪性肝炎、2型糖尿病(T2D)、慢性阻塞性肺病(COPD)、骨关节炎、骨质疏 松、纤维化、阿尔茨海默病、帕金森病、痴呆动脉粥样硬化、心血管疾病、关节炎、类风湿性关节炎、，牙周炎、白内障、骨质疏松、纤维化、肝硬化、特发性肺纤维化、心脏纤维化、子宫纤维化、瘢痕、关节纤维化、慢性肾病、克罗恩病、瘢痕疙瘩、骨髓纤维化、腹膜后纤维化、硬皮病、硬化、慢性伤口(如糖尿病足溃疡)、慢性皮肤纤维化、皮肤纤维化、皮肤老化、，非酒精性脂肪性肝炎(NASH)、脱发、组织萎缩、更年期、卵巢老化、原发性卵巢功能不全、子宫内膜增生、子宫腺肌病和肌萎缩、神经退行性疾病以及任何其他由损伤、手术、癌症、先天性、发育性和环境组织损失或损伤引起的疾病。
  6. 一种用于促进细胞或组织健康的组合物，其包含治疗剂X或其药学上可接受的盐；其中，所述治疗剂X选自通式(I)或通式(II)化合物或其药学上可接受的盐，
  7. 权利要求6所述组合物，其中组合物可用于提高身体耐力、缓解疲劳、缓解运动疲劳、补充营养、改善外观(例如但不限于健美、去皱纹、增 加发量)。
  8. 权利要求6-7所述的组合物，其中，所述组合物能够促进细胞或组织扩增或增长。
  9. 权利要求6-8所述的组合物，其中，所述组合物能够让细胞或持续扩增至少4天、5天、6天、8天、9天、10天、20天、30天、40天、50天、100天、150天、200天、300天、400天或甚至更多天。
  10. 权利要求6-9所述药物组合，其中，所述药物组合可用于预防或治疗细胞或组织纤维化。
  11. 一种向个体施用权利要求6-10中任一权利要求所述物质组合物的方法，其中所述组合物作为保健品、膳食补充剂、运动饮料或营养制剂施用。
  12. 权利要求11所述方法，其中所述组合物被添加到蛋白质源或食物中。
  13. 一种向个体施用权利要求6-10中任一权利要求所述物质组合物的方法，其中将所述组合物添加到化妆品、保健化妆品或药妆品中。
PCT/CN2023/105802 2022-07-14 2023-07-05 一种用于抵抗衰老的组合物及其用途或方法 WO2024012317A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210829713.3 2022-07-14
CN202210829713 2022-07-14

Publications (1)

Publication Number Publication Date
WO2024012317A1 true WO2024012317A1 (zh) 2024-01-18

Family

ID=89498892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/105802 WO2024012317A1 (zh) 2022-07-14 2023-07-05 一种用于抵抗衰老的组合物及其用途或方法

Country Status (2)

Country Link
CN (1) CN117398391A (zh)
WO (1) WO2024012317A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10120579A (ja) * 1996-10-18 1998-05-12 Dokutaazu Kosumeteikusu:Kk 津液改善用皮膚外用剤
CN1429556A (zh) * 2001-12-18 2003-07-16 有限会社大长企画 强肌肉剂和抗炎症剂
US20080031968A1 (en) * 2005-04-01 2008-02-07 The Brigham And Women's Hospital, Inc. Methods for increasing cellular energy expenditure
CN105611910A (zh) * 2013-08-08 2016-05-25 盖尔德姆疗法有限公司 包含胆汁酸-脂肪酸缀合物的抗老化组合物
WO2019161211A2 (en) * 2018-02-15 2019-08-22 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis and nash
US20210121493A1 (en) * 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
US20210347811A1 (en) * 2018-10-08 2021-11-11 New York University Steroid compounds as treg modulators and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10120579A (ja) * 1996-10-18 1998-05-12 Dokutaazu Kosumeteikusu:Kk 津液改善用皮膚外用剤
CN1429556A (zh) * 2001-12-18 2003-07-16 有限会社大长企画 强肌肉剂和抗炎症剂
US20080031968A1 (en) * 2005-04-01 2008-02-07 The Brigham And Women's Hospital, Inc. Methods for increasing cellular energy expenditure
CN105611910A (zh) * 2013-08-08 2016-05-25 盖尔德姆疗法有限公司 包含胆汁酸-脂肪酸缀合物的抗老化组合物
US20210121493A1 (en) * 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
WO2019161211A2 (en) * 2018-02-15 2019-08-22 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis and nash
US20210347811A1 (en) * 2018-10-08 2021-11-11 New York University Steroid compounds as treg modulators and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BÁRCENA CLEA, LÓPEZ-OTÍN CARLOS, KROEMER GUIDO: "Methionine restriction for improving progeria: another autophagy-inducing anti-aging strategy?", AUTOPHAGY, LANDES BIOSCIENCE, US, vol. 15, no. 3, 4 March 2019 (2019-03-04), US , pages 558 - 559, XP093127640, ISSN: 1554-8627, DOI: 10.1080/15548627.2018.1533059 *
GONZALES, E. ET AL.: "Oral Cholic Acid for Hereditary Defects of Primary Bile Acid Synthesis: A Safe and Effective Long-term Therapy", GASTROENTEROLOGY, vol. 137, no. 4, 31 October 2009 (2009-10-31), XP026661269, DOI: 10.1053/j.gastro.2009.07.043 *

Also Published As

Publication number Publication date
CN117398391A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
JP5894341B2 (ja) コラーゲンペプチド、エラスチンペプチドおよびプロテオグリカンを含む組成物
JP5646459B2 (ja) 疾患及び障害を治療するためのアンギオゲニン又はアンギオゲニンアゴニストの使用
Besouw et al. Cysteamine toxicity in patients with cystinosis
CN105899223A (zh) 转移性前列腺癌的治疗
WO2015166887A1 (ja) ケルセチン配糖体を含有する筋萎縮抑制剤
KR101290745B1 (ko) 라말린을 함유하는 염증질환 또는 면역질환의 예방 또는 치료용 약학 조성물
JP2009502958A (ja) ストレスの治療または管理の方法
US20220241229A1 (en) Methods and Compositions for Altering Senescence Associated Secretory Phenotype
JP2023022318A (ja) ペプチドｗｋｄｅａｇｋｐｌｖｋを含む組成物
WO2012043808A1 (ja) 熱ショックタンパク質発現誘導剤
WO2024012317A1 (zh) 一种用于抵抗衰老的组合物及其用途或方法
CN111417647A (zh) 新型senolytic肽
EP3360548A1 (en) Muscle damage or muscle fatigue inhibitor
WO2022145439A1 (ja) 筋萎縮抑制剤及び筋萎縮を抑制させる方法
US20170007521A1 (en) Use of metal complexes which are mimetics of sod as food agents and as cosmetics
WO2018066707A1 (ja) 老化抑制剤、軟部組織の石灰化抑制剤、及び肺組織破壊抑制剤
TWI624477B (zh) Peptide composition and use thereof
JP6944240B2 (ja) Ｇａｂａを有効成分とする生体組織の線維性構造タンパク質の含有量を維持または増加するための剤
Yan et al. Melatonin exerts neuroprotective effects in mice with spinal cord injury by activating the Nrf2/Keap1 signaling pathway via the MT2 receptor
JP4786028B2 (ja) 抗アレルギー剤
KR20180015594A (ko) 스쿠알렌을 함유하는 근기능 향상 및 근육 손상 예방용 조성물
WO2022242711A1 (en) Methods for ameliorating and preventing age‐related muscle degeneration
JP2013203729A (ja) コラーゲン産生促進剤
JP6903675B2 (ja) 皮膚細胞分化促進用組成物及び皮膚細胞分化促進物質のスクリーニング方法
US10532040B2 (en) Methods of treating cancer with herbacetin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23838809

Country of ref document: EP

Kind code of ref document: A1